Severe Abdominal Complications in Lung Transplant Recipients.

Exp Clin Transplant

>From the Division of Pulmonology, University Hospital Zurich, and the Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Published: December 2024

Objectives: Lung transplant is a complex procedure with potential for substantial postoperative complications, including abdominal issues. Although previous studies have suggested that preexisting gastrointestinal conditions may be associated with a high risk of posttransplant complications, the evidence remains inconsistent. We aimed to explore the incidence rates, risk factors, and outcomes of abdominal complications within the first year following lung transplant.

Materials And Methods: We conducted a retrospective cohort study at the University Hospital Zurich of 68 lung transplant recipients who experienced abdominal complications within 1 year after transplant. Data were collected from medical records on baseline demographic and clinical characteristics, including pretransplant gastrointestinal and hepatobiliary diseases. We used descriptive statistics (Fisher exact test, chi-square test, and Cramer V test) to assess outcome details, such as the timing and type of abdominal complications, surgical interventions, and associations with pretransplant conditions.

Results: Abdominal complications occurred at a mean of 43 days posttransplant, with bowel ischemia and perforation as the most common reasons for posttransplant surgical intervention. Symptoms leading to surgery included nausea and abdominal pain, and 1 of 8 patients with abdominal surgery (12.5%) died after surgery. Notably, no significant associations were found between pretransplant factors (ie, gastrointestinal disease, hepatobiliary disease, body mass index >24, smoking status, peripheral vascular disease, and diabetes) and the occurrence of posttransplant abdominal surgery. Effect size analyses indicated very weak associations, suggesting that these pretransplant conditions are not strong predictors of postoperative abdominal complications.

Conclusions: Our results showed that preexisting gastrointestinal and hepatobiliary conditions, along with other common pretransplant factors, were not significant predictors of abdominal complications following lung transplant. Future studies should focus on intraoperative and immediate postoperative factors and should explore the role of minimally invasive surgical techniques and potential benefits of earlier or more comprehensive pretransplant screening.

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.2024.0246DOI Listing

Publication Analysis

Top Keywords

abdominal complications
24
lung transplant
16
abdominal
10
complications
8
complications lung
8
transplant recipients
8
preexisting gastrointestinal
8
complications year
8
gastrointestinal hepatobiliary
8
associations pretransplant
8

Similar Publications

Introduction: Bowel perforation due to migrated biliary stent is a rare complication. Here, we report a case of duodenal and ascending colonal perforation due to biliary stent migration.

Case Presentation: A 35-year-old man is complaining of right upper abdominal pain presented to the gastroenterology department.

View Article and Find Full Text PDF

A low-grade appendiceal mucinous neoplasm (LAMN) is a rare condition, occurring in 0.08-4.1% of appendectomy cases.

View Article and Find Full Text PDF

Background: Obesity is a growing global health issue, with a prevalence rate of 28.8% in Jordan. Bariatric surgery is the most effective treatment for morbid obesity, yet complications such as postoperative bleeding and leakage remain significant concerns.

View Article and Find Full Text PDF

Mycotic aneurysms are rare but severe complications that can arise from systemic bacterial infections, including those caused by Salmonella species. These aneurysms can progress rapidly and are associated with high mortality. A 62-year-old man with poorly controlled type 2 diabetes mellitus presented to the hospital in septic shock.

View Article and Find Full Text PDF

Background: Acute hepatic porphyria (AHP) is characterized by debilitating and potentially life-threatening neurovisceral attacks, possible chronic symptoms, and long-term complications. In a phase 1/2 open-label extension (OLE) study and the phase 3 ENVISION study, givosiran led to sustained improvement in annualized attack rate and quality of life (QOL) measures. To capture the patient experience of symptoms and impacts of AHP, and any changes experienced during treatment with givosiran, qualitative interviews were conducted with study participants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!